## PYRIZINOSTATIN: A NEW INHIBITOR OF PYROGLUTAMYL PEPTIDASE

Takaaki Aoyagi<sup>†,††</sup>, Masahiro Hatsu<sup>\*,†</sup>, Chiaki Imada<sup>†</sup>, Hiroshi Naganawa<sup>†</sup>, Yoshiro Okami<sup>†</sup> and Tomio Takeuchi<sup>†</sup>

<sup>†</sup>Institute of Microbial Chemistry,
3-14-23 Kamiosaki, Shinagawa-ku, Tokyo 141, Japan
<sup>††</sup>Department of Hygienic Chemistry,
Showa College of Pharmaceutical Sciences,
3-chome, Higashitamagawagakuen,
Machida-shi, Tokyo 194, Japan

(Received for publication June 30, 1992)

While screening the culture filtrate of microorganisms for specific inhibitors against various kinds of enzymes, we found a variety of new compounds that specifically inhibit the target  $enzymes^{1 \sim 3}$ . Among such compounds was included benarthin<sup>4,5)</sup>, an inhibitor of pyroglutamyl peptidase (PGpeptidase). We have further continued screening for inhibitors of PG-peptidase, and discovered another new inhibitor, which we named pyrizinostatin, from culture filtrate of the microbial strain SA2289, which had been isolated from a marine soil and confirmed to belong to the genus Streptomyces. The structure of pyrizinostatin was elucidated by NMR spectral analysis and X-ray analysis, and was determined as 2,4,4a,8-tetrahydro-2,6,8-trimethyl-4a-(2-oxopropyl)pyrimido[5,4-e]-1,2,4-triazine-3,5,7(6H)-trione (Fig. 1).

The activity of PG-peptidase was measured according to the method of  $EXTERKATE^{6}$ , as reported previously<sup>4</sup>), in order to determine a concentration of the inhibitor required for 50% inhibition (IC<sub>50</sub>).

Pyrizinostatin was produced by shaken culture of SA2289 in a medium containing soluble starch 1.0%,  $K_2HPO_4$  0.2%,  $MgSO_4 \cdot 7H_2O$  0.1%,  $(NH_4)_2SO_4$  0.2%, yeast extract 0.1%,  $FeSO_4 \cdot 7H_2O$  0.0001%,  $MnCl_2 \cdot 4H_2O$  0.0001%,  $ZnSO_4 \cdot 7H_2O$  0.0001%,

Fig. 1. Structure of pyrizinostatin.



 $CaCO_3$  0.2% and Jamarin S (Jamarin Laboratory) 0.01%, adjusted to pH 7.2 with 5 N NaOH before sterilization.

The flow diagram for the isolation is shown in Scheme 1. The broth was harvested after 96 hours and filtered to give broth filtrate (14 liters, pH 5.9). The inhibitor in broth filtrate was absorbed on Diaion HP-20, inhibitor was eluted with  $0 \sim 75\%$ MeOH. The solution containing inhibitor was absorbed on a column of Sepabeads SP-206 and eluted with  $0 \sim 90\%$  MeOH. The eluate solution containing active compound was concentrated to give a crude powder.

The crude powder was subjected to centrifugal partition chromatography (solvent system; BuOH-AcOH- $H_2O$  and CHCl<sub>3</sub>-MeOH- $H_2O$ ). The fractions containing pyrizinostatin were concentrated to yield a yellow powder. Further purification of the yellow powder was effected by Sephadex LH-20 with MeOH. The fractions containing pyrizinostatin were concentrated, and crystallization from MeOH gave pure pyrizinostatin (40.2 mg) as colorless crystals.

Physico-chemical properties of pyrizinostatin are summarized in Table 1. The molecular formula of pyrizinostatin was determined as  $C_{11}H_{15}N_5O_4$  by HRFAB-MS and elemental analysis. The substance gave positive color reactions to molybdophosphoric acid-sulfalic acid and GREIG-LEABACK<sup>7</sup> reagents, and negative to ninhydrin reagent. Pyrizinostatin is





Crude powder (458 mg)

Centrifugal partition chromatography BuOH - AcOH - H<sub>2</sub>O CHCl<sub>3</sub> - MeOH - H<sub>2</sub>O

Yellow powder (96 mg)

Sephadex LH-20 MeOH Crystallized from MeOH

Pyrizinostatin (colorless crystals, 40.2 mg)

Appearance	Colorless crystal	
MP	188~190°C	
$[\alpha]_{\rm D}^{24}$	$-15.6^{\circ}$ (c 1.0, MeOH)	
Molecular formula	$C_{11}H_{15}N_5O_4$	
Elemental analysis		
Calcd for $C_{11}H_{15}N_5O_4$ :	C 46.92, H 5.33, N 24.89	
Found:	C 46.54, H 5.60, N 24.64	
HRFAB-MS $(m/z)$		
Calcd for $C_{11}H_{16}N_5O_4$ :	282.1208	
Found:	282.1205	
UV spectrometry	UV $\lambda_{\max}^{MeOH}$ nm ( $\varepsilon$ ),	
	280 (4,600)	
Color reaction	Mo-H <sub>2</sub> SO <sub>4</sub> ,	
	GREIG-LEABACK	
Solubility	Soluble; H <sub>2</sub> O, CHCl <sub>3</sub> ,	
	MeOH, DMSO	
Rfª	0.72	

Table 1. Physico-chemical properties of pyrizinostatin.

<sup>a</sup> On silica gel TLC plate (Merck Art. No. 5715) with BuOH - AcOH - H<sub>2</sub>O (4:1:2) as eluent.

Table 2. <sup>13</sup>C (100 MHz) and <sup>1</sup>H (400 MHz) NMR data of pyrizinostatin in CDCl<sub>3</sub>.

Position	<sup>13</sup> C	М	$^{1}\mathrm{H}(J = \mathrm{Hz})$
N2-CH <sub>3</sub>	37.0	q	3.31
3	151.5	s	
N4-H		_	5.75
4a	54.9	s	
5	166.2	\$	_
N6-CH <sub>3</sub>	28.8	q	3.27
7	149.8	s	_
N8-CH <sub>3</sub>	30.4	q	3.34
8a	138.6	s	_
9	49.6	t	2.95 (16.0)
	_		3.24 (16.0)
10	202.7	s	
11	30.8	q	2.13

Chemical shifts in ppm from TMS.

M: Multiplicity.

soluble in  $H_2O$ , CHCl<sub>3</sub>, MeOH and DMSO, but insoluble in EtOAc, ether and hexane. The <sup>13</sup>C and <sup>1</sup>H NMR data for pyrizinostatin are summarized in Table 2.

The inhibitory activities of pyrizinostatin showed an IC<sub>50</sub> value of  $1.8 \,\mu\text{g/ml}$  against PG-peptidase. As shown in Fig. 2, the inhibition of pyrizinostatin against PG-peptidase is noncompetitive. Pyrizinostatin inhibited the growth of *Shigella sonnei* JS11764 and *Proteus vulgaris* OX19 at 100  $\mu$ g/ml, but had no antimicrobial activity against other bacteria and fungi. Pyrizinostatin had a low toxicity; no deaths occurred after its intravenous injection of Fig. 2. Lineweaver-Burk plot of inhibition of PGpeptidase by pyrizinostatin.

Pyrizinostatin:  $\bigcirc$ ;  $4 \mu g/ml$ ,  $\blacksquare$ ;  $3 \mu g/ml$ ,  $\blacktriangle$ ;  $2 \mu g/ml$ ,  $\bigcirc$ ;  $0 \mu g/ml$ .  $Km = 4.34 \times 10^{-5} \text{ M}$ .



100 mg/kg to mice.

## Acknowledgments

This work was supported by the Grant-in-Aid for Scientific Research on Priority Areas No. 02259101 from the Ministry of Education, Science and Culture, Japan.

## References

- UMEZAWA, H. (Ed.): Enzyme Inhibitors of Microbial Origin. pp. 15~110, University Tokyo Press, 1972
- AOYAGI, T. & H. UMEZAWA: Structures and activities of protease inhibitors of microbial origin. *In* Proteases and Biological Control. *Ed.*, E. REICH *et al.*, pp. 429~454, Cold Spring Harbor Laboratory, 1975
- AOYAGI, T.: Biological significance of proteases and their inhibitors. Proc. Jpn. Soc. Invest. Dermatol. 10: 77~82, 1986
- AOYAGI, T.; M. HATSU, F. KOJIMA, C. HAYASHI, M. HAMADA & T. TAKEUCHI: Benarthin: A new inhibitor of pyroglutamyl peptidase. I. Taxonomy, fermentation, isolation and biological activities. J. Antibiotics 45: 1079 ~ 1083, 1992
- HATSU, M.; H. NAGANAWA, T. AOYAGI & T. TAKEUCHI: Benarthin: A new inhibitor of pyroglutamyl peptidase: II. Physico-chemical properties and structure determination. J. Antibiotics 45: 1084~1087, 1992
- 6) EXTERKATE, F. A.: A modified colorimetric method for the determination of pyrrolidone carboxylyl peptidase activity in bacteria. Anal. Biochem. 52: 321~326, 1973
- GREIG, C. G. & D. H. LEABACK: Use of chlorine in the detection of compounds on paper chromatograms. Nature 188: 310~311, 1960